Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05493553 · ClinicalTrials.gov registry record · NA
Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability
A NA study of Healthy and Impaired Glucose Tolerance, sponsored by Unicity International.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05493553: Completed NA study of Healthy and Impaired Glucose Tolerance, sponsored by Unicity International.
NCT05493553 is a NA study of Healthy and Impaired Glucose Tolerance that has completed, run by Unicity International. The registered enrollment target is 50 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05493553, a NA study of Healthy and Impaired Glucose Tolerance, has completed, sponsored by Unicity International.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors for impaired fasting glucose.
Primary Outcome
Within-subject change in glucose coefficient of variation (CV)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Dietary supplement regimen
- OTHER Dietary supplement and intermittent fasting regimen
Study Locations (1)
Illinois
- Biofortis Clinical Research - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2022-09-29 |
| Phase | NA |
What the finished NCT05493553 record still lists
NCT05493553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Dietary supplement regimen is the first listed.
NCT05493553 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05493553 about?
NCT05493553 is a clinical study titled "Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability". The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors for impaired fasting glucose.
What is the current status of trial NCT05493553?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2022-08-08. Estimated completion is 2022-09-29.
What conditions does trial NCT05493553 study?
This clinical trial studies the following conditions: Healthy, Impaired Glucose Tolerance.
What interventions are being tested in trial NCT05493553?
The interventions under investigation include: Dietary supplement regimen (DIETARY_SUPPLEMENT), Dietary supplement and intermittent fasting regimen (OTHER).
Who is sponsoring clinical trial NCT05493553?
This trial is sponsored by Unicity International, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05493553 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05493553's enrollment target sits among peer trials
50 448th of 1090 higher than 618 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI